Expert Ratings for Corcept Therapeutics
Portfolio Pulse from Benzinga Insights
Corcept Therapeutics (NASDAQ:CORT) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $31.75, an increase of 8.55% over the past month. The ratings are based on the company's predicted earnings and revenue streams over the next five years.

August 25, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics has received mostly bullish ratings from analysts, indicating a positive outlook for the company's stock.
The bullish ratings from analysts indicate a positive outlook for Corcept Therapeutics' stock. Analysts base their ratings on predicted earnings and revenue streams over the next five years, and the increase in the average price target suggests they expect the company's performance to improve.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100